AHR and cancer: This is supported by Wnt/β-catenin-driven cancer models with mutations of the tumor suppressor APC and the deletion of AhR [83,84], and additional mouse cancer models where the loss of AhR activity resulted in enhanced tumorigenesis and elevated Wnt signaling [115,116,117,125,131].